CONCLUSIONS
In re-operative AVR via upper partial re-sternotomy after CABG with patent bypass grafts, MIrAVR may prevent fatal complications, such as graft injury, by minimizing tissue detachment. Although further development of the TAVI technology is expected to change treatment methods in the future, MIrAVR after CABG is currently a viable treatment option.